Genomic and Epigenomic Biomarkers of Toxicology and Disease

36 Price, A. (2011). What is the role of radiotherapy in malignant pleural mesothelioma. The Oncologist 16 (3): 359–365.

37 Rascoe, P.A., Jupiter, D., Cao, X., Littlejohn, J.E., and Smythe, W.R. (2012). Molecular pathogenesis of malignant mesothelioma. Expert Rev. Mol. Med. 14: e12.

38 Reid, G., Pel, M.E., Kirschner, M.B. et al. (2013). Restoring expression of miR-16: A novel approach to therapy for malignant pleural mesothelioma. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 24 (12): 3128–3135.

39 Robinson, B.W. and Lake, R.A. (2005). Advances in malignant mesothelioma. N. Engl. J. Med. 353 (15): 1591–1603.

40 Santarelli, L., Staffolani, S., Strafella, E. et al. (2015). Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma. Lung Cancer J. Int. Assoc. Study Lung Cancer 90 (3): 457–464.

41 Santarelli, L., Strafella, E., Staffolani, S. et al. (2011). Association of miR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. PloS One 6 (4): e18232.

42 Schramm, A., Opitz, I., Thies, S. et al. (2010). Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. Eur. J. Cardiothorac. Surg: Off. J. Eur. Assoc. Cardiothorac. Surg. 37 (3): 566–572.

43 Sempere, L.F. and Korc, M. (2013). A method for conducting highly sensitive microRNA in situ hybridization and immunohistochemical analysis in pancreatic cancer. Methods Mol. Biol. 980: 43–59.

44 Singh, A., Bhattacharyya, N., Srivastava, A. et al. (2019). MicroRNA-215-5p treatment suppresses mesothelioma progression via the MDM2-p53-signaling axis. Mol. Ther. J. Am. Soc. Gene Ther. 27 (9): 1665–1680.

45 Tanaka, N., Toyooka, S., Soh, J. et al. (2013). Downregulation of microRNA-34 induces cell proliferation and invasion of human mesothelial cells. Oncol. Rep. 29 (6): 2169–2174.

46 Tomasetti, M., Staffolani, S., Nocchi, L. et al. (2012). Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients. Clin. Biochem. 45 (7-8): 575–581.

47 Truini, A., Coco, S., Alama, A. et al. (2014). Role of microRNAs in malignant mesothelioma. CMLS 71 (15): 2865–2878.

48 Ueno, T., Toyooka, S., Fukazawa, T., et al. (2014). Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma. Acta Med Okayama. 68 (1): 23–26.

49 Van Roosbroeck, K., Pollet, J., and Calin, G.A. (2013). miRNAs and long noncoding RNAs as biomarkers in human diseases. Expert Rev. Mol. Diagn. 13 (2): 183–204.

50 Weber, D.G., Casjens, S., Johnen, G. et al. (2014). Combination of miR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis. PloS One 9 (12): e114483.

51 Weber, D.G., Gawrych, K., Casjens, S. et al. (2017). Circulating miR-132-3p as a candidate diagnostic biomarker for malignant mesothelioma. Dis. Markers 2017: 9280170.

52 Wright, C.M., Kirschner, M.B., Cheng, Y.Y. et al. (2013). Long non coding RNAs (lncRNAs) are dysregulated in malignant pleural mesothelioma (MPM). PloS One 8 (8): e70940.

53 Wu, C., Jin, B., Chen, L. et al. (2013). MiR-30d induces apoptosis and is regulated by the Akt/FOXO pathway in renal cell carcinoma. Cell. Signal. 25 (5): 1212–1221.

54 Zhang, P., Garnett, J., Creighton, C.J. et al. (2014). EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis. J. Pathol. 232 (3): 308–318.

55 Zöller, M. (2013). Pancreatic cancer diagnosis by free and exosomal miRNA. World J. Gastrointest. Pathophysiol. 4 (4): 74–90.

Текст предоставлен ООО «ЛитРес».

Прочитайте эту книгу целиком, купив полную легальную версию на ЛитРес.

Безопасно оплатить книгу можно банковской картой Visa, MasterCard, Maestro, со счета мобильного телефона, с платежного терминала, в салоне МТС или Связной, через PayPal, WebMoney, Яндекс.Деньги, QIWI Кошелек, бонусными картами или другим удобным Вам способом.